Holen Sie sich die Stockscreener-App
7.90
1.80%
0.14
Handel nachbörslich:
7.90
Schlusskurs vom Vortag:
$7.76
Offen:
$7.76
24-Stunden-Volumen:
8.22M
Relative Volume:
0.75
Marktkapitalisierung:
$5.34B
Einnahmen:
$6.55B
Nettoeinkommen (Verlust:
$-530.20M
KGV:
-10.16
EPS:
-0.7777
Netto-Cashflow:
$495.00M
1W Leistung:
-7.28%
1M Leistung:
+2.20%
6M Leistung:
-48.70%
1J Leistung:
-49.03%
1-Tages-Spanne:
$7.595
$7.915
1-Wochen-Bereich:
$7.46
$8.85
52-Wochen-Spanne:
$7.265
$15.93
Avantor Inc Stock (AVTR) Company Profile
Firmenname
Avantor Inc
Sektor
Telefon
(610) 386-1700
Adresse
RADNOR CORPORATE CENTER, BUILDING ONE, RADNOR, PA
Compare AVTR vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVTR
Avantor Inc
|
7.90 | 5.25B | 6.55B | -530.20M | 495.00M | -0.7777 |
ISRG
Intuitive Surgical Inc
|
482.22 | 169.58B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
152.14 | 44.05B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
44.76 | 39.09B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
75.80 | 36.98B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
219.85 | 31.98B | 5.40B | 1.49B | 1.78B | 10.12 |
Avantor Inc Stock (AVTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2026-01-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-17 | Herabstufung | Jefferies | Hold → Underperform |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-30 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-08-01 | Herabstufung | Jefferies | Buy → Hold |
| 2025-04-29 | Herabstufung | Goldman | Buy → Neutral |
| 2025-04-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-04-28 | Herabstufung | Stifel | Buy → Hold |
| 2025-04-28 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-11 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-07-31 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-21 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Hold |
| 2022-10-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-09-14 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-09-09 | Herabstufung | Cleveland Research | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-30 | Fortgesetzt | Raymond James | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-08-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-04 | Eingeleitet | Goldman | Buy |
| 2021-04-29 | Hochstufung | Stifel | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-08-02 | Eingeleitet | Cleveland Research | Neutral |
| 2019-06-14 | Eingeleitet | Janney | Buy |
| 2019-06-12 | Eingeleitet | Raymond James | Outperform |
| 2019-06-11 | Eingeleitet | Goldman | Buy |
| 2019-06-11 | Eingeleitet | Guggenheim | Buy |
| 2019-06-11 | Eingeleitet | JP Morgan | Overweight |
| 2019-06-11 | Eingeleitet | Jefferies | Buy |
| 2019-06-11 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-06-11 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-11 | Eingeleitet | SunTrust | Buy |
| 2019-06-11 | Eingeleitet | UBS | Buy |
| 2019-06-11 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Avantor Inc Aktie (AVTR) Neueste Nachrichten
Earnings Preview: Avantor to Report Financial Results Pre-market on April 29 - Moomoo
Avantor names Ludovic Brellier as EVP and transformation officer By Investing.com - Investing.com Australia
Avantor, Inc. Announces Executive Change and Files SEC Form 8-K – April 2026 - Minichart
Avantor Appoints New Executive VP and Transformation Leader - TipRanks
Avantor® announces Ludovic Brellier as executive vice president, bioscience & medtech products (BMP) & chief transformation officer - marketscreener.com
Avantor (NYSE: AVTR) taps Ludovic Brellier to lead BMP and transformation - Stock Titan
Danaher executive joins Avantor to lead product unit and Revival - Stock Titan
Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Avantor rallies as Engine Capital takes 3% stake, pushes for strategy to double stock - MSN
Stanley Capital Management, LLC's Avantor Inc(AVTR) Holding History - GuruFocus
Avantor (AVTR) Market Performance | Avantor Inc. posts 0.4% EPS miss, $6.55B Q4 revenueADR - Xã Thanh Hà
Avantor Expands Masterflex Portfolio to Streamline Bioprocessing - Zacks Investment Research
Avantor CEO Emmanuel Ligner's First Observations on Company Strategy and Market OutlookNews and Statistics - IndexBox
Avantor Expands North American Quality Control Capabilities - MyChesCo
Analysts hold neutral stance on Avantor, Inc. (AVTR) amid lower valuation expectations - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Avantor, Inc. (AVTR) And Encourages Investors to Connect - ACCESS Newswire
Avantor (AVTR) Q3 2025 Earnings Transcript - The Globe and Mail
Avantor Unifies Masterflex Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing - marketscreener.com
Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing - Sahm
Avantor, Inc.'s (NYSE:AVTR) Popularity With Investors Is Clear - 富途牛牛
How Investors Are Reacting To Avantor (AVTR) Localizing Advanced Microbial and Stability Testing in St. Louis - simplywall.st
Avantor, Inc. (AVTR) Stock Analysis: Evaluating Growth Potential Amid A 24.14% Upside - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Encourages Avantor, Inc. (AVTR - The National Law Review
Technical Reactions to AVTR Trends in Macro Strategies - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Avantor, Inc. (AVTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Avantor stock up as new lab capabilities improve biopharma support - MSN
Avantor Expands St Louis Quality Control Capabilities To Accelerate Biopharma Manufacturing - BioPharma APAC
Avantor Inc stock (US05352A1007): Why its life sciences leadership matters more now for investors - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages Avantor, Inc. (AVTR) Investors to Inquire about Securities Investigation - ACCESS Newswire
Avantor, Inc. $AVTR Shares Sold by Lightrock Netherlands B.V. - MarketBeat
Avantor Price Target Cut to $7.00/Share From $8.50 by Barclays - Moomoo
Research Tools & Consumables Stocks Q4 In Review: Avantor (NYSE:AVTR) Vs Peers - Yahoo Finance
Avantor, Inc. (NYSE:AVTR) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Avantor India Expands its Strategic Collaboration with Parafilm to Serve the Indian Laboratory Consumables Market - ANTARA News
Avantor slides on revised outlook, revenue miss - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avantor, Inc. (AVTR) And Encourages Investors to Reach Out - ACCESS Newswire
Barclays Maintains Avantor(AVTR.US) With Sell Rating, Cuts Target Price to $7 - Moomoo
A Look At Avantor’s Valuation As It Expands Its North American Quality Control Hub - Yahoo Finance
Avantor Stock Up as New Lab Capabilities Improve Biopharma Support - Yahoo Finance
Radnor-based Avantor opens St. Louis facility - Pennsylvania Business Report -
Avantor, Inc. $AVTR Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Avantor expands quality control testing at St. Louis facility By Investing.com - Investing.com Australia
Avantor Inc stock (US05352A1007): Why supply chain resilience matters more now for investors - AD HOC NEWS
Avantor Adds Microbial, Stability Testing Capabilities to St. Louis Manufacturing Site - marketscreener.com
Avantor Inc Expands U S Biomanufacturing Infrastructure With Expanded Stability and Microbial Testing Facility - marketscreener.com
Avantor expands strategic collaboration with Parafilm to serve Indian lab consumables market - BioSpectrum India
Avantor expands quality control testing at St. Louis facility - Investing.com
Avantor Inc stock (US05352A1007): Why supply chain resilience matters more now - AD HOC NEWS
Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility - Financial Times
Analysts Hold Neutral Stance on Avantor, Inc. (AVTR) Amid Lower Valuation Expectations - Insider Monkey
Avantor Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility - Bitget
Finanzdaten der Avantor Inc-Aktie (AVTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):